Drug Profile
Mivebresib - AbbVie
Alternative Names: ABB075; ABBV-075Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antineoplastics; Pyridines; Small molecules; Sulfones
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Myelofibrosis
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy) in South Africa (PO, Tablet)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy) in South Korea (PO, Tablet)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy) in USA (PO, Tablet)